Auro Laboratories Ltd

Auro Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Auro Laboratories Ltd

₹ 264 4.00%
12 Jun - close price
aurolabs.com BSE: 530233
About

Incorporated in 1989, Auro Laboratories Ltd is in the business of Bulk Drugs[1]

Key Points

Business Overview:[1]
ALL manufactures generic Active Pharmaceutical Ingredients (APIs), with a focus on anti-diabetics like Metformin HCL, a first-line treatment for type 2 diabetes. It also offers toll and custom manufacturing of APIs and intermediaries on a contract basis.

Website BSE
  • Market Cap ₹ 165 Cr.
  • Current Price ₹ 264
  • High / Low ₹ 317 / 159
  • Stock P/E 45.2
  • Book Value ₹ 74.4
  • Dividend Yield 0.00 %
  • ROCE 9.42 %
  • ROE 8.15 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter

Cons

  • Stock is trading at 3.55 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of -10.7% over past five years.
  • Company has a low return on equity of 10.6% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
13.52 10.18 13.41 17.98 12.06 5.72 3.10 3.05 7.40 2.77 8.84 9.39 9.83
11.17 9.02 10.38 13.90 9.65 4.39 2.38 2.60 6.59 2.74 6.49 5.33 6.50
Operating Profit 2.35 1.16 3.03 4.08 2.41 1.33 0.72 0.45 0.81 0.03 2.35 4.06 3.33
OPM % 17.38% 11.39% 22.60% 22.69% 19.98% 23.25% 23.23% 14.75% 10.95% 1.08% 26.58% 43.24% 33.88%
0.62 0.36 0.32 0.42 0.40 0.20 0.31 0.14 0.13 0.42 0.98 0.18 0.52
Interest 0.13 0.27 0.35 0.44 -0.32 0.25 0.28 0.25 0.30 0.28 0.96 1.52 1.49
Depreciation 0.30 0.27 0.27 0.27 0.28 0.27 0.27 0.27 0.29 0.27 0.65 0.98 0.90
Profit before tax 2.54 0.98 2.73 3.79 2.85 1.01 0.48 0.07 0.35 -0.10 1.72 1.74 1.46
Tax % 29.53% 27.55% 27.84% 27.70% 18.60% 24.75% 25.00% 28.57% -11.43% 0.00% 58.14% -12.07% 32.88%
1.78 0.71 1.97 2.73 2.32 0.75 0.36 0.05 0.39 -0.11 0.72 1.95 0.97
EPS in Rs 2.86 1.14 3.16 4.38 3.72 1.20 0.58 0.08 0.63 -0.18 1.16 3.13 1.56
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
32.65 27.91 35.47 40.79 46.82 43.79 54.25 50.87 52.89 53.64 19.40 30.74
29.71 25.11 31.03 34.43 39.83 37.51 43.01 46.24 48.50 42.96 16.00 20.74
Operating Profit 2.94 2.80 4.44 6.36 6.99 6.28 11.24 4.63 4.39 10.68 3.40 10.00
OPM % 9.00% 10.03% 12.52% 15.59% 14.93% 14.34% 20.72% 9.10% 8.30% 19.91% 17.53% 32.53%
0.24 0.42 0.53 0.51 0.96 0.97 0.76 1.09 0.94 1.50 0.66 1.87
Interest 1.66 1.66 1.18 1.21 0.87 0.58 0.46 0.83 0.81 0.74 1.08 4.25
Depreciation 0.72 0.68 0.86 0.93 1.01 1.02 1.04 1.02 1.07 1.09 1.10 2.81
Profit before tax 0.80 0.88 2.93 4.73 6.07 5.65 10.50 3.87 3.45 10.35 1.88 4.81
Tax % 0.00% 0.00% 72.01% 25.16% 27.51% 27.96% 31.62% 26.61% 28.99% 24.64% 2.13% 26.61%
0.80 0.88 0.82 3.53 4.40 4.05 7.18 2.84 2.44 7.79 1.84 3.53
EPS in Rs 1.28 1.41 1.32 5.66 7.06 6.50 11.52 4.56 3.91 12.50 2.95 5.66
Dividend Payout % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: 1%
5 Years: -11%
3 Years: -17%
TTM: 58%
Compounded Profit Growth
10 Years: 15%
5 Years: -13%
3 Years: 14%
TTM: 98%
Stock Price CAGR
10 Years: 28%
5 Years: 19%
3 Years: 44%
1 Year: -3%
Return on Equity
10 Years: 14%
5 Years: 10%
3 Years: 11%
Last Year: 8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 6.23 6.23 6.23 6.23 6.23 6.23 6.23 6.23 6.23 6.23 6.23 6.23
Reserves 1.47 2.35 3.18 6.75 11.18 15.27 22.35 25.29 27.97 35.73 36.74 40.12
16.41 12.62 4.95 9.20 8.09 3.16 3.16 13.78 6.41 26.25 42.72 63.30
4.67 4.49 12.45 8.23 7.97 7.68 10.15 9.66 15.38 17.52 13.40 11.43
Total Liabilities 28.78 25.69 26.81 30.41 33.47 32.34 41.89 54.96 55.99 85.73 99.09 121.08
9.80 9.13 13.00 13.02 14.59 14.24 13.56 13.61 12.62 22.15 21.06 75.19
CWIP 0.82 3.33 0.23 1.07 0.12 0.12 0.13 3.68 7.67 32.68 56.48 14.48
Investments 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.01
18.11 13.18 13.53 16.27 18.71 17.93 28.15 37.62 35.65 30.85 21.50 31.40
Total Assets 28.78 25.69 26.81 30.41 33.47 32.34 41.89 54.96 55.99 85.73 99.09 121.08

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-0.78 7.88 6.49 6.05 6.87 9.30 12.82 -6.59 3.28 18.81 5.75 2.11
-0.73 -2.44 -2.20 -3.04 -3.19 -2.21 -3.51 -5.34 -5.08 -38.67 -24.45 -14.78
0.53 -5.34 -3.81 -1.77 -1.83 -5.52 -0.46 9.79 -8.18 19.09 17.69 14.04
Net Cash Flow -0.98 0.09 0.47 1.24 1.86 1.58 8.85 -2.14 -9.98 -0.77 -1.02 1.37
Free Cash Flow -1.55 5.36 4.86 4.25 5.25 8.63 12.44 -11.20 -0.79 18.81 5.75 -13.04
CFO/OP -27% 281% 146% 95% 98% 148% 114% -142% 75% 176% 169% 21%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 94.80 66.04 79.13 74.90 66.26 48.18 49.12 97.65 85.57 91.11 176.67 108.65
Inventory Days 89.37 86.72 21.65 22.00 42.98 60.54 32.60 47.32 120.27 113.24 145.45 815.53
Days Payable 56.12 72.03 80.26 78.26 66.19 70.67 73.51 54.12 117.41 85.34 246.11 281.88
Cash Conversion Cycle 128.05 80.73 20.52 18.64 43.05 38.04 8.20 90.86 88.44 119.01 76.01 642.29
Working Capital Days 39.13 26.68 67.20 64.70 63.46 51.09 29.40 36.59 104.28 35.86 -14.30 6.41
ROCE % 10.74% 11.21% 23.06% 32.51% 29.11% 24.84% 38.87% 12.20% 9.92% 20.38% 3.85% 9.42%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Production Volume
Kg

Log in to view insights

Please log in to see hidden values.

Login
Product Concentration (Metformin HCL Revenue Contribution)
%
Export Share of Total Revenue
%
Installed Capacity - Metformin HCL
MTPA
Historical Total Installed Capacity
Kg
Capacity Utilization - Metformin HCL
MTPA
Workforce (Employee Count)
Number

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
52.09% 52.09% 52.09% 52.15% 52.15% 52.15% 52.15% 52.17% 52.17% 52.17% 52.17% 52.17%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
47.90% 47.92% 47.90% 47.85% 47.84% 47.84% 47.84% 47.82% 47.82% 47.82% 47.80% 47.82%
No. of Shareholders 10,50110,2729,9059,4419,3359,2669,2659,1028,9168,8608,6408,405

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings